Foundayo is a drug owned by Eli Lilly And Co. It is protected by 1 US drug patent filed in 2026 out of which none have expired yet. Foundayo's patents will be open to challenges from 01 April, 2030. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 26, 2037. Details of Foundayo's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| USRE50455 | NA |
Sep, 2037
(11 years from now) | Active |
FDA has granted several exclusivities to Foundayo. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Foundayo, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Foundayo.
Exclusivity Information
Foundayo holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2031. Details of Foundayo's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 01, 2031 |
US patents provide insights into the exclusivity only within the United States, but
Foundayo is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Foundayo's family patents as well as insights into
ongoing legal events
on those patents.
Foundayo's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Foundayo's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Sep 26, 2037 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Foundayo Generics:
There are no approved generic versions for Foundayo as of now.
About Foundayo
Foundayo is a drug owned by Eli Lilly And Co. Foundayo uses Orforglipron Calcium as an active ingredient. Foundayo was launched by Eli Lilly in 2026.
Approval Date:
Foundayo was approved by FDA for market use on 01 April, 2026.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Foundayo is 01 April, 2026, its NCE-1 date is estimated to be 01 April, 2030.
Active Ingredient:
Foundayo uses Orforglipron Calcium as the active ingredient. Check out other Drugs and Companies using Orforglipron Calcium ingredient
Dosage:
Foundayo is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 9MG BASE | TABLET | Prescription | ORAL |
| EQ 2.5MG BASE | TABLET | Prescription | ORAL |
| EQ 5.5MG BASE | TABLET | Prescription | ORAL |
| EQ 14.5MG BASE | TABLET | Prescription | ORAL |
| EQ 0.8MG BASE | TABLET | Prescription | ORAL |
| EQ 17.2MG BASE | TABLET | Prescription | ORAL |